关于HIV感染者使用卡博特韦和利匹韦林长效治疗的问答
本文综述长效卡博特韦和利匹韦林(首个获批临床使用的全注射抗逆转录病毒方案)在HIV感染者中的使用与管理数据,涵盖临床试验数据及首批真实世界经验,聚焦使用长效药物的理由、临床实践中的实施以及治疗患者的长期监测。
要点
- 长效卡博特韦和利匹韦林需重新组织门诊和门诊服务。
- 需正确选择可接受长效卡博特韦和利匹韦林治疗的患者。
- 关于疗效与耐受性监测及病毒学失败和短暂病毒血症的管理仍有争议。
核心结论
- 长效卡博特韦和利匹韦林是首个获批临床使用的全注射抗逆转录病毒方案,其使用需重新组织门诊和门诊服务。
- 关于接受长效药物治疗的HIV感染者管理仍有多个问题待明确,包括正确选择可治疗患者、疗效与耐受性监测的最佳方式以及病毒学失败和短暂病毒血症的管理是否应不同于口服方案。
研究设计与样本
- 本文为综述,回顾了长效卡博特韦和利匹韦林在不同场景下使用与管理的数据,包括临床试验数据和首批可获得的真实世界经验。
主要发现
- 现代抗逆转录病毒治疗正在演变,允许使用新药物制剂和口服治疗以外的替代给药途径。
- 长效卡博特韦和利匹韦林是这一新给药途径的试验案例,也是一项对HIV感染者生活质量有影响的创新。
临床怎么用
- 本文聚焦于使用长效药物的理由、在临床实践中实施其使用以及对治疗患者的长期监测。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Modern ART is evolving, allowing the use of new drug formulations and alternative routes of administration to oral therapy. Long-acting (LA) cabotegravir and rilpivirine, the first fully injectable antiretroviral regimen approved for clinical use, is a test case for this new route of administration, and an innovation with implications for the quality of life of people with HIV (PWH). However, its use requires a reorganization of outpatient clinics and outpatient services, and a number of issues remain to be defined regarding the management of PWH on LA drugs, including the correct selection of people who can be treated with LA cabotegravir and rilpivirine. There is also ongoing debate about the best way to monitor both efficacy and tolerability of LA treatment and whether the management of virological failures and blips should be different from that reserved for oral regimens. The present article reviews the data on the use and management of LA cabotegravir and rilpivirine in different settings, with a review of clinical trial data and also the first available real-life experiences. The article focuses on the following: the reasons for the use of LA drugs; the implementation of their use in clinical practice; and the monitoring of treated people over time.
引用
- Taramasso L, Bonora S, Cingolani A, et al. Question and answers on long-acting therapy with cabotegravir and rilpivirine in people with HIV. J Antimicrob Chemother. 2025. PMID: 39888371. doi:10.1093/jac/dkaf025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。